<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Is Medtronic’s 17% Rally Justified After Strong Earnings and Bullish Guidance? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Is Medtronic’s 17% Rally Justified After Strong Earnings and Bullish Guidance?</h2>
    <div class="badge">2025-09-15T10:38:23+00:00</div>
    <ul>
      <li>With a steady closing price of $94.03, the stock has edged up by 1.1% over both the past week and the last 30 days.</li>
<li>Analysts project the company’s free cash flow to rise steadily, reaching roughly $6.94 billion by 2028.</li>
<li>With the stock currently trading at $94.03, this represents a 3.2% discount to its underlying value according to the DCF analysis.</li>
<li>The bigger story, however, is a 17.2% rise year-to-date and a 7.8% bump over the past year.</li>
<li>Currently, Medtronic’s last twelve months free cash flow stands at $5.41 billion.</li>
<li>Over a ten-year view, longer-term estimates that are extrapolated beyond direct analyst forecasts suggest free cash flow could approach $8.94 billion by 2035.</li>
<li>Applying the two-stage Free Cash Flow to Equity model, these projections yield an estimated intrinsic value of $97.18 per share.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Is Medtronic’s 17% Rally Justified After Strong Earnings and Bullish Guidance?\n• With a steady closing price of $94.03, the stock has edged up by 1.1% over both the past week and the last 30 days.\n• Analysts project the company’s free cash flow to rise steadily, reaching roughly $6.94 billion by 2028.\n• With the stock currently trading at $94.03, this represents a 3.2% discount to its underlying value according to the DCF analysis.\n• The bigger story, however, is a 17.2% rise year-to-date and a 7.8% bump over the past year.\n• Currently, Medtronic’s last twelve months free cash flow stands at $5.41 billion.\n• Over a ten-year view, longer-term estimates that are extrapolated beyond direct analyst forecasts suggest free cash flow could approach $8.94 billion by 2035.\n• Applying the two-stage Free Cash Flow to Equity model, these projections yield an estimated intrinsic value of $97.18 per share." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/medtronic-17-rally-justified-strong-103823032.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>